185 related articles for article (PubMed ID: 31116679)
1. What can we learn about influenza infection and vaccination from transcriptomics?
Rao S; Ghosh D; Asturias EJ; Weinberg A
Hum Vaccin Immunother; 2019; 15(11):2615-2623. PubMed ID: 31116679
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
3. Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics.
Horns F; Dekker CL; Quake SR
Cell Rep; 2020 Jan; 30(3):905-913.e6. PubMed ID: 31968262
[TBL] [Abstract][Full Text] [Related]
4. Differential gene expression elicited by children in response to the 2015-16 live attenuated versus inactivated influenza vaccine.
Cole KS; Martin JM; Horne WT; Lin CJ; Nowalk MP; Alcorn JF; Zimmerman RK
Vaccine; 2017 Dec; 35(49 Pt B):6893-6897. PubMed ID: 29132989
[TBL] [Abstract][Full Text] [Related]
5. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination.
Esposito S; Principi N
Vaccine; 2011 Oct; 29(43):7535-41. PubMed ID: 21820478
[TBL] [Abstract][Full Text] [Related]
6. Hemagglutinin-specific CD4
Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
[TBL] [Abstract][Full Text] [Related]
7. Immune response to influenza vaccination in an elderly population.
Brydak LB; Machała M; Myśliwska J; Myśliwski A; Trzonkowski P
J Clin Immunol; 2003 May; 23(3):214-22. PubMed ID: 12797543
[TBL] [Abstract][Full Text] [Related]
8. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
9. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
10. Response to influenza vaccine in people with non-protective HI antibody titers.
Baldo V; Baldovin T; Floreani A; Minuzzo M; Trivello R
Eur J Epidemiol; 2006; 21(11):843-5. PubMed ID: 17082899
[TBL] [Abstract][Full Text] [Related]
11. Influenza infection in human host: challenges in making a better influenza vaccine.
Virk RK; Gunalan V; Tambyah PA
Expert Rev Anti Infect Ther; 2016; 14(4):365-75. PubMed ID: 26885890
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
Front Immunol; 2018; 9():3103. PubMed ID: 30761157
[TBL] [Abstract][Full Text] [Related]
13. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine.
Jegaskanda S; Reading PC; Kent SJ
J Immunol; 2014 Jul; 193(2):469-75. PubMed ID: 24994909
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific patterns of gene expression following influenza vaccination.
Wen F; Guo J; Li Z; Huang S
Sci Rep; 2018 Sep; 8(1):13517. PubMed ID: 30202120
[TBL] [Abstract][Full Text] [Related]
15. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
16. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
17. Purified viral neuraminidase vaccine to control influenza.
Arora DJ
Can Med Assoc J; 1979 Dec; 121(12):1575-9. PubMed ID: 394829
[TBL] [Abstract][Full Text] [Related]
18. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.
Pedersen GK; Madhun AS; Breakwell L; Hoschler K; Sjursen H; Pathirana RD; Goudsmit J; Cox RJ
J Infect Dis; 2012 Jul; 206(2):158-66. PubMed ID: 22551811
[TBL] [Abstract][Full Text] [Related]
19. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
20. Human genetics and responses to influenza vaccination: clinical implications.
Lambkin R; Novelli P; Oxford J; Gelder C
Am J Pharmacogenomics; 2004; 4(5):293-8. PubMed ID: 15462607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
